Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 180

Sort by

Sort Order Select

Journal Articles

Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial

Blood (2024) 144 (Supplement 1): 3563.

https://doi.org/10.1182/blood-2024-200574

Published: 2024

Journal Articles

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Blood (2024) 144 (Supplement 1): 730.

https://doi.org/10.1182/blood-2024-201936

Published: 2024

Journal Articles

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Blood (2024) 144 (Supplement 1): 309.

https://doi.org/10.1182/blood-2024-204943

Published: 2024

Journal Articles

Pediatric T-cell lymphoblastic lymphomas but not leukemias harbor TRB :: NOTCH1 fusions with unfavorable outcome

Blood (2024) 144 (13): 1412–1417.

https://doi.org/10.1182/blood.2024025307

Published: 2024

Includes: Supplemental data

Journal Articles

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Blood (2024) 143 (17): 1738–1751.

https://doi.org/10.1182/blood.2023021952

Published: 2024

Includes: Supplemental data

Journal Articles

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Blood (2023) 142 (Supplement 1): 825.

https://doi.org/10.1182/blood-2023-181524

Published: 2023

Journal Articles

STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young

Shunsuke Kimura, Petri Pölönen, Lindsey Montefiori, Kenneth Caldwell, Ilaria Iacobucci, Chelsey Chen, Anthony Brown, Katie Han, Yen-Chun Liu, Yunchao Chang, Zhongshan Cheng, Zhou Yinmei, Chun Shik Park, Sharnise Mitchell, Noemi Reyes, Allen Yeoh, Andishe Attarbaschi, Andrew Moore, Atsushi Manabe, Barbara Buldini, Kean Hui Chiew, Chi Kong Li, Ching-Hon Pui, Chunxu Qu, Daisuke Tomizawa, Elisabeth Paietta, Franco Locatelli, Gabriele Escherich, Gao Qingsong, Hannah Elisa Muhle, Hanne Vibeke Marquart, Hester A. de Groot-Kruseman, Jacob M. Rowe, Jan Stary, Jan Trka, John Kim Choi, Jules P.P. Meijerink, Junko Takita, Katarzyna Pawinska-Wasikowska, Kjeld Schmiegelow, Mariko Eguchi, Martin Schrappe, Martin Zimmermann, Masatoshi Takagi, Melissa Maybury, Michael Svaton, Michaela Reiterova, Michal Kicinski, Motohiro Kato, Orietta Spinelli, Pauline Mazilier, Paul G. Thomas, Riccardo Masetti, Rishi Sury Kotecha, Rob Pieters, Sarah Elitzur, Selina M Luger, Shuhong Shen, Sima Jeha, Steven M. Kornblau, Szymon Skoczen, Takako Miyamura, Tiffaney Vincent, Toshihiko Imamura, Valentino Conter, Yanjing Tang, Zhaohui Gu, Kathryn G. Roberts, David T. Teachey, Kristine R Crews, Cheng Cheng, Jun J. Yang, Hiroto Inaba, Charles G. Mullighan

Blood (2023) 142 (Supplement 1): 845.

https://doi.org/10.1182/blood-2023-178688

Published: 2023

Journal Articles

BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease

Blood (2022) 140 (Supplement 1): 9179–9180.

https://doi.org/10.1182/blood-2022-158926

Published: 2022

Journal Articles

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Blood (2022) 140 (Supplement 1): 109–111.

https://doi.org/10.1182/blood-2022-166583

Published: 2022

Journal Articles

ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010

Blood (2022) 140 (Supplement 1): 3247–3249.

https://doi.org/10.1182/blood-2022-166234

Published: 2022

Journal Articles

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Blood (2022) 140 (Supplement 1): 11676–11678.

https://doi.org/10.1182/blood-2022-163142

Published: 2022

Journal Articles

Recurrent DNMT3B Alterations Are Associated with Unfavorable Outcome in Dicentric (9;20)-Positive Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Željko Antić, Alena van Bömmel, Konstantin Riege, Jana Lentes, Charlotte Schröder, Julia Alten, Lara Fuhrmann, Martin Zimmermann, Cornelia Eckert, Gunnar Cario, Martin Schrappe, Brigitte Schlegelberger, Steve Hoffmann, Anke K. Bergmann

Blood (2022) 140 (Supplement 1): 9185–9186.

https://doi.org/10.1182/blood-2022-163404

Published: 2022

Journal Articles

Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance

Amir Enshaei, Javier Martinez Martínez Elicegui, Esther Anguiano, Jude Gibson, Mirella Ampatzidou, Michael Doubek, Adele K. Fielding, Edoardo La Sala, Elizabeth Middleton, Anita W. Rijneveld, Amin T. Turki, Ajay Vora, Martin Zimmermann, Anthony V. Moorman

Blood (2022) 140 (Supplement 1): 6369–6370.

https://doi.org/10.1182/blood-2022-157680

Published: 2022

Journal Articles

Ph-like and IKZF1plus Features in Children with Down Syndrome and B Cell Precursor Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 6367–6368.

https://doi.org/10.1182/blood-2022-169131

Published: 2022

Journal Articles

The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis

Oriol Alejo-Valle, Karoline Weigert, Raj Bhayadia, Michelle Ng, Hasan Issa, Christoph Beyer, Stephan Emmrich, Konstantin Schuschel, Christian Ihling, Andrea Sinz, Martin Zimmermann, Claudia Wickenhauser, Marius Flasinski, Eniko Regenyi, Maurice Labuhn, Dirk Reinhardt, Marie-Laure Yaspo, Dirk Heckl, Jan-Henning Klusmann

Blood (2022) 139 (5): 651–665.

https://doi.org/10.1182/blood.2021012231

Published: 2022

Includes: Supplemental data

Journal Articles

MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia

Blood (2021) 138 (20): 1953–1965.

https://doi.org/10.1182/blood.2020007591

Published: 2021

Includes: Supplemental data

Journal Articles

TP53 and KRAS Variants at Initial Diagnosis Identify an Ultra-High Risk Group of Pediatric T-Lymphoblastic Leukemia (T-ALL)

Tamara Kempter, Joachim B. Kunz, Paulina Richter-Pechanska, Katarzyna Tomska, Tobias Rausch, Busra Erarslan-Uysal, Cornelia Eckert, Martin Zimmermann, Martin Stanulla, Martin Schrappe, Gunnar Cario, Gabriele Escherich, Renate Kirschner-Schwabe, Martina U. Muckenthaler, Jan O. Korbel, Andreas E. Kulozik

Blood (2021) 138 (Supplement 1): 1315.

https://doi.org/10.1182/blood-2021-148420

Published: 2021

Journal Articles

Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance

Blood (2021) 137 (17): 2347–2359.

https://doi.org/10.1182/blood.2020005381

Published: 2021

Includes: Supplemental data

Journal Articles

Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141774

Published: 2020

Journal Articles

Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group

Mareike Rasche, MD, Emma Steidel, Martin Zimmermann, Jean-Pierre Bourquin, MD PhD, Heidrun Boztug, Iveta Janotová, Edward A. Kolb, MD, Thomas Lehrnbecher, Nils Von Neuhoff, PhD, Naghmeh Niktoreh, Nora Muehlegger, Lucie Sramkova, MD, Jan Stary, MD PhD, Christiane Walter, MSc, Ursula Creutzig, MD PhD, Michael Dworzak, MD PhD, Dirk Reinhardt, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-139317

Published: 2020

NARROW

Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Pediatric T-cell lymphoblastic lymphomas but not leukemias harbor TRB :: NOTCH1 fusions with unfavorable outcome

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young

BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Recurrent DNMT3B Alterations Are Associated with Unfavorable Outcome in Dicentric (9;20)-Positive Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance

Ph-like and IKZF1plus Features in Children with Down Syndrome and B Cell Precursor Acute Lymphoblastic Leukemia

The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis

MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia

TP53 and KRAS Variants at Initial Diagnosis Identify an Ultra-High Risk Group of Pediatric T-Lymphoblastic Leukemia (T-ALL)

Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance

Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only